A toxic version of a certain protein may affect brain, spinal cord and skeletal muscle tissues differently, leading to the ...

RNS60 is an experimental therapy designed to boost the formation of new mitochondria and restore energy production in nerve ...

LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing ...

Sanofi stopped a Phase 2 study of oditrasertib in relapsing and progressive MS after it failed to lower blood NfL levels ...

Oditrasertib, which blocks the inflammatory RIPK1 protein, earlier this year also failed a Phase II trial in amyotrophic ...

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditras | Sanofi has stopped a phase 2 trial of the ...

Denali Therapeutics said on Thursday its partner Sanofi has discontinued a mid-stage study testing their experimental drug to ...

True to its history of reinvention and repurposing, Pharmaust will be renamed Neurizon Therapeutics after shareholders ...

A team of researchers from Penn State College of Medicine found that misfolded versions of a protein exhibit tissue-specific toxicity linked to cell degeneration that may be linked to the development ...

Researchers at the Francis Crick Institute and the UCL Queen Square Institute of Neurology have developed DNA molecules which contain "invisibility cloak" sequences, preventing healthy cells from ...

Hall, founder of Beacon of Hope for ALS, aims to lift people up and help them after their diagnosis. Amyotrophic lateral ...